Deutsche Bank
FULC icon

Deutsche Bank’s Fulcrum Therapeutics FULC Stock Holding History

Deutsche Bank’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$212K Buy
57,182
+4,801
+9% +$18K ﹤0.01% 3056
2026
Q2 		$192K Buy
52,381
+3,553
+7% +$21.6K ﹤0.01% 3278
2026
Q1 		$375K Sell
48,828
-238,268
-83% -$2.21M ﹤0.01% 2724
2025
Q4 		$3.25M Buy
287,096
+1,767
+0.6% +$18K ﹤0.01% 1515
2025
Q3 		$2.63M Buy
285,329
+6,078
+2% +$44K ﹤0.01% 1624
2025
Q2 		$1.92M Sell
279,251
-561
-0.2% -$3K ﹤0.01% 1732
2025
Q1 		$806K Sell
279,812
-5,679
-2% -$20.9K ﹤0.01% 2258
2024
Q4 		$1.34M Sell
285,491
-424
-0.1% -$1.56K ﹤0.01% 2083
2024
Q3 		$1.02M Sell
285,915
-563,278
-66% -$4.18M ﹤0.01% 2105
2024
Q2 		$5.26M Buy
849,193
+26,095
+3% +$198K ﹤0.01% 1228
2024
Q1 		$7.77M Hold
823,098
– – ﹤0.01% 1112
2023
Q4 		$5.56M Buy
+823,098
New +$3.65M ﹤0.01% 1210
2023
Q2 		– Sell
-31,733
Closed -$90.4K – 3847
2023
Q1 		$90.4K Buy
31,733
+12,965
+69% +$116K ﹤0.01% 3375
2022
Q4 		$137K Sell
18,768
-4,962
-21% -$32.4K ﹤0.01% 3177
2022
Q3 		$192K Buy
23,730
+2,280
+11% +$16.3K ﹤0.01% 2969
2022
Q2 		$105K Sell
21,450
-3,849
-15% -$37.6K ﹤0.01% 3498
2022
Q1 		$598K Sell
25,299
-2,088
-8% -$29.6K ﹤0.01% 2641
2021
Q4 		$484K Sell
27,387
-9,208
-25% -$182K ﹤0.01% 2878
2021
Q3 		$1.03M Buy
36,595
+23,445
+178% +$444K ﹤0.01% 2585
2021
Q2 		$138K Buy
13,150
+3,203
+32% +$32.4K ﹤0.01% 3991
2021
Q1 		$117K Sell
9,947
-891
-8% -$11K ﹤0.01% 3889
2020
Q4 		$127K Buy
10,838
+3,011
+38% +$34K ﹤0.01% 3716
2020
Q3 		$62K Buy
7,827
+1,417
+22% +$17.1K ﹤0.01% 3773
2020
Q2 		$117K Buy
6,410
+1,774
+38% +$27.9K ﹤0.01% 3369
2020
Q1 		$56K Buy
4,636
+3,126
+207% +$50K ﹤0.01% 3487
2019
Q4 		$25K Buy
1,510
+309
+26% +$2.95K ﹤0.01% 4232
2019
Q3 		$7K Buy
+1,201
New +$13.3K ﹤0.01% 4585

Other funds holding FULC

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank's FULC Position: Q3 2026 in Review

Deutsche Bank increased its Fulcrum Therapeutics (FULC) stake by 9.2% in Q3 2026, buying an estimated $18K and bringing the position to 57,182 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Deutsche Bank first reported a position in FULC in Q3 2019 and has held it in 27 quarters since. The position peaked at $7.77M in Q1 2024. 42 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Deutsche Bank held 57,182 shares of Fulcrum Therapeutics worth $212K as of Q3 2026.
  • Deutsche Bank bought 4,801 Fulcrum Therapeutics shares in Q3 2026, an estimated $18K.
  • Fulcrum Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3056 holding.
  • Deutsche Bank first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Deutsche Bank's Fulcrum Therapeutics position peaked at $7.77M in Q1 2024.
  • 42 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.